ArticleJournal of health, population, and nutrition2025
A retrospective cohort study on the clinical efficacy of Shanhuang Jiangzhi tablets and Atorvastatin calcium tablets in the treatment of carotid atherosclerosis.
Article in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe efficacy and safety of the combination therapy of Shanhuang Jiangzhi tablets and atorvastatin in treating primary hyperlipidemia and carotid atherosclerosis remain unclear and require further investigation. MATERIALS AND
methodsA retrospective cohort study was conducted using the medical records of the neurology wards from 1 January 2014 to 30 June 2022. Patients were divided into observation and control groups based on inclusion and exclusion criteria. The control group received atorvastatin calcium tablets at a dose of 20 mg per day, whereas the observation group received the same dose of atorvastatin plus Shanhuang Jiangzhi tablets at 2.4 g per day. The treatment period for both groups was 2 years. Blood lipid profiles and carotid ultrasound indicators were compared before and after treatment. All the data were statistically analysed using SPSS 26.0.
resultsThis study included 319 atherosclerosis patients, with 162 in the observation group (average age 62.84 ± 11.90 years, 44.4% men) and 157 in the control group (average age 62.62 ± 10.33 years, 52.2% men). No significant differences were found in baseline characteristics between the two groups (p > 0.05). Following treatment, significant reductions in total cholesterol (4.38 ± 1.07 vs. 4.71 ± 1.11) and low-density lipoprotein cholesterol levels (2.78 ± 0.80 vs. 3.11 ± 0.92) were observed in the observation group compared with the control group (p < 0.05). Additionally, improvements in the carotid intima-media thickness (IMT) (1.63 ± 0.09 vs. 1.80 ± 0.05) and plaque scores (4.06 ± 0.26 vs. 4.17 ± 0.29) were more pronounced in the observation group (p < 0.05).
conclusionThis study investigated the use of Shanhuang Jiangzhi tablets combined with atorvastatin calcium for carotid atherosclerosis, offering effective options for traditional Chinese medicine in managing atherosclerosis and hyperlipidaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.